Table 1 Study cohort characteristics
RTX-treated RA patients (n=51) | Non-RTX-treated RA patients (n=24) | p value | |
|---|---|---|---|
Age, years (median, IQR) | 67 (57-76) | 59 (51-63) | 0.022* |
Gender: Female/Male | 45 (88%)/6 (12%) | 15 (62.5%)/9 (37.5%) | 0.014* |
RA duration, years (median, IQR) | 22 (13-29) | 5 (2-14) | <0.001* |
Treatments: | |||
bDMARDS: | |||
- RTX | 100% | 0 | |
- Others (Etanercept, Abatacept, Tocilizumab | 0 | 7 (29%) | 0.850 |
o Monotherapy | - | 4 (16.7%) | |
Concomitant csDMARDS: | |||
- Methotrexate | 20 (39.2%) | 11 (45.8%) | |
- Leflunomide | 6 (11.8%) | 2 (8.3%) | |
- Others (Sulfasalazine, Hydroxychloroquine) | 6 (11.8%) | 0 | |
- None | 19 (37.3%) | 11 (45.8%) | |
Prednisone use: | 0.710 | ||
- No | 38 (74.5%) | 17 (70.8%) | |
- 5 mg/day | 7 (13.7%) | 5 (20.8%) | |
- 5 mg/day | 6 (11.8%) | 2 (8.3%) | |
DAS 28 (mean, SD) | 2.96 (1.26) | 3.48 (1.55) | 0.150 |
Number of vaccine doses | Median: 3 | Median: 3 | 0.034* |
- 1 or 2 | 3 (5.9%) | 7 (29.2%) | |
- 3 | 34 (66.7%) | 13 (54.2%) | |
- 4 | 14 (27.5%) | 4 (16.7%) | |
History of SARS-CoV-2 infection | 25 (49%) | 14 (58.3%) | 0.770 |
- Mild symptoms | 19 (37.3%) | 10 (41.7%) | |
- Hospitalization/O2 | 5 (9.8%) | 3 (12.5%) | |
- Intensive care | 1 (2%) | 1 (4.2%) | |
Number of “SARS-CoV-2 boost” (cumulative number of SARS-CoV-2 vaccine doses and infections) | Median: 4 | Median: 3 | 0.099 |
- < 3 | 0 (0%) | 2 (8.3%) | |
- 3 | 51 (100%) | 22 (91.7%) | |
SARS-CoV-2 serology level (BAU/mL) (mean, SD) | 562 (768) | 839 (645) | 0.034* |
SARS-CoV-2 serology positivity | 30 (59%) | 13/14 (93%)# | 0.024* |
Time between sample collection and last SARS-CoV-2 boost, months (median, IQR) | 5 (3-8) | 4 (2-9.75) | 0.490 |
- 0-6 months | 30 (58.8%) | 15 (62.5%) | |
- 6-12 months | 18 (35.3%) | 7 (29.1%) | |
- 12-18 months | 3 (5.9%) | 2 (8.3%) | |
Number of RTX infusions (median, IQR) | 10 (6-16) | NA | NA |
Cumulative dose of RTX, g (median, IQR) | 11 (6-20) | NA | NA |
Time between sample collection and last RTX infusion, months (median, IQR) | 9.3 (6.5-13.1) | NA | NA |
Time between last RTX infusion and last vaccine dose, months (median, IQR) | 5.6 (3.2-7.8) | NA | NA |
CD19 B-cell count, % (mean, SD) | 6.84 (9.54) | NA | NA |
Patients with CD19 B-cell count < 6% (clinical criteria) | 30 (59%) | NA | NA |
IgG titer, g/L (mean, SD) | 8.75 (3.35) | NA | NA |